{"id":"NCT00488514","sponsor":"GlaxoSmithKline","briefTitle":"Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents","officialTitle":"Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07-13","primaryCompletion":"2009-08-01","completion":"2009-08-20","firstPosted":"2007-06-20","resultsPosted":"2010-09-06","lastUpdate":"2017-05-18"},"enrollment":656,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine Disorders"],"interventions":[{"type":"DRUG","name":"Combination Tablet of Treximet (sumatriptan/naproxen sodium)","otherNames":["Combination Product (sumatriptan succinate / naproxen sodium)"]}],"arms":[{"label":"Active Drug","type":"OTHER"}],"summary":"This study was designed to determine long-term safety of TREXIMET (sumatriptan/naproxen sodium) in adolescents for the acute treatment of migraine.","primaryOutcome":{"measure":"Number of Participants With the Indicated Drug-related Adverse Events","timeFrame":"Baseline through End of Study (up to Month 12)","effectByArm":[{"arm":"6 Month Completer Population","deltaMin":93,"sd":null},{"arm":"12 Month Completer Population","deltaMin":46,"sd":null},{"arm":"Safety Population","deltaMin":170,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":16},"locations":{"siteCount":77,"countries":["United States"]},"refs":{"pmids":["21797863"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":622},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Nausea","Sinusitis","Oropharyngeal pain"]}}